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Ubiquitination of protein species in regulating signal transduction pathways is 
universally accepted as fundamental during normal development and has been 
implicated in the progression of many human diseases, such as cancer.  One particular 
pathway that has received much attention in this context is TGF-β signalling, 
particularly during the regulation of EMT and tumour progression.  While E3-
ubiquitin ligases offer themselves as potential therapeutic targets (based on their 
ability to confer substrate specificity), much remains to be unveiled regarding 
mechanisms that culminate in their regulation. With this in mind, the focus of this 
review highlights the significance of a recently described group of E3-ubiquitin ligase 
isoforms in the context of the TGF-β pathway regulation. Moreover, we now broaden 
these observations to incorporate a growing number of protein-isoforms within the 
ubiquitin ligase superfamily as a whole, and discuss what relevance they may have in 
defining a new ‘iso-ubiquitinome’. 
Introduction 
Physiological Transforming Growth Factor-beta (TGF-β) cytokine signalling 
is quite pleiotropic in it’s activity, whereby it plays a key role in modulation of the 
immune response in addition to regulating tissue homeostasis by determining the 
balance between cell loss and renewal 1.  Of significance are its effects on the cell 
cycle and apoptosis (as in the instance of genotoxic stress and cytotoxic 
chemotherapy), thereby contributing to the neoplastic transformation of cells in 
addition to modulating their motility and invasiveness thereafter by driving Epithelial-
Mesenchymal Transition (EMT) 2.  TGF-β initiates signalling by occupying TGFβ-
receptor II (TGFβ-RI1), to which TGFβ-receptor I (TGFβ-RI) is recruited. The 
Intracellular Domain (ICD) of TGFβ-RI is phosphorylated by TGFβ-RII kinase 
activity, which then phosphorylates and activates regulatory-Smad2 and Smad3 
(rSmads) resulting in their nuclear translocation, in a Smad4-dependant manner 3,4.   
Subsequently, the modulation of gene expression by the Smads then ensues with the 
aid of specific co-activators such as p300 and CBP 5 and co-repressors such as Ski 6, 
SnoN 7 and TGIF 5.  Down-regulation of TGF signalling is under strict control by 
inhibitory Smad7, which is induced after continual TGF-β stimulation 8 and can act 
by physically associating with TGFβ-R1, thereby blocking receptor-mediated activity 
9.   
  Physiologically, while TGFβ-RII activation represents one key signalling step 
in TGF-β signalling, Smad4-mediated translocation of rSmads and the subsequent 
dampening of TGF-β signalling by Smad7 (Figure 1) are also fundamental regulatory 
steps shown to be instrumental in the development of TGF-β mediated disease 10,11.  
Recently, these intermediates have therefore received much attention in light of how 
they are regulated by the ubiquitination-proteasomal pathway.  Moreover, supported 
by the observation that certain E3-Ubiquitin ligases such as Smurf2, WWP1 and 
WWP2 12-14 have been linked to TGF-β signalling pathway activity and tumour 
progression, highlighting the importance of the ubiquitination pathway in disease and 
potentially providing an ‘open niche’ for the development of intervening therapeutics.  
For example, while the drug Velcade/Bortezomib 15,16 broadly targets the 26s subunit 
of the proteasome, as upstream regulators of the proteasome, E3-ubiquitin ligase-
directed therapeutics may hold greater potential in being more specific to certain 
signalling pathways and therefore may demonstrate greater efficacy with possibly less 
side effects.  Additionally, further understanding the mechanistic and biological input 
of the E1/E2/E3 protein isoforms in modulating the ubiquitination pathway and the 
‘ubiquitinome’, may lead to identification of alternative targets and a new generation 
of therapeutic agents that may offer even greater specificity in the treatment of 
disease. 
TGF-β  and Epithelial-Mesenchymal Transition of cells  
EMT is a key reprogramming process that regulates morphological plasticity 
upon modulating the delamination of epithelial cells resulting in them undertaking a 
mesenchymal phenotype, thus enhancing their migratory potential.  Moreover, 
mesenchymal cells have the ability to repolarise by MET (Mesenchymal-Epithelial 
Transition), which (along with EMT) has been recognised as being fundamental 
during embryogenesis, development and evolution 17.  However, during disease 
progression, EMT and MET can be devastating (as in the case of cancer), where 
transformed epithelial cells can spread as tumour metastases and become established 
at distal sites throughout the host.       
Underpinning this is TGF-β signalling, which has received particular attention 
over the recent years, which can suppress uncontrolled proliferation in normal cells 
while conversely promoting tumour metastasis by stimulating cells to undergo EMT.  
Typically, EMT induction arises by normal epithelial cells (and fibroblast cells) 
responding to TGF-β by synthesising and secreting numerous cytokines, growth 
factors and Extra-cellular Matrix (ECM) components into the tumour cells 
microenvironment aiding tumour progression 18,19.  At the molecular level, this occurs 
by a number of changes in gene expression levels of a number of key products 20-23, 
namely matrix metalloproteases 24,25, N-CAM 26, UPA 27,28, PAI-1 29,30, Collagen IV 
31, Fibronectin 18, E-Cadherin 32,  Vimentin  33 and α-Smooth Muscle Actin 34. 
While TGF-β potently activates signalling through the Smad proteins, other 
signalling networks that directly result in the modulation of the above genes central to 
EMT, are also activated which result in the modulation of key signalling 
intermediates and pathways such as Rho GTPases 35,36, PI3K/AKT 37, NF-κB 38, MAP 
Kinases 39,40. 
 
The Ubiquitination Pathway 
The ubiquitination of proteins is evolving to be intrinsic in modulating not just 
the stability of targeted proteins, but also their sub-cellular localisation and 
consequently their ability to modulate signal transduction pathways in mammalian 
systems.  Broadly, a three-tiered system exists, which results in the sequential transfer 
of activated ubiquitin to the target protein-which is colloquially referred to as the 
‘Ubiquitinome’ (Figure 2). 
In addition to ubiquitin, small molecules termed ‘Ubiquitin-Like Modifiers’ 
(ULMs) have also been described, which contain ubiquitin-like domains and also 
target substrate proteins via the conserved E1-E3 enzyme system of the 
‘ubiquitinome’ with differing outcomes.  Examples of these include SUMO, NEDD, 
ISG15, ATG8, ATG12, FAT10, URM1, UFM1, MNSF-β, which have been shown to 
modulate intracellular protein localisation, turnover, signal transduction, and 
transcriptional activation 41. 
While ULMs have also been recognised for their ability to regulate the steady-
state levels of targeted proteins, for simplicity and clarity, the focus here shall be 
centred around ubiquitin (for other ULMs, see 41). 
 
E1 Activating Enzymes 
The first step in ubiquitination of target proteins involves the Mg++/ and ATP-
dependant activation of the 76 amino-acid ubiquitin protein 42 by the process of 
Adenylation, which is driven by an E1-Ubiquitin activating enzyme 43.  Eight known 
mammalian members of the E1 activating enzyme family exist, all of which share 
significant sequence conservation (see 44).  However, UBE1 45 46,47 and the recently 
discovered UBA6 (also named UBE1L2 or E1L2 48-50 are the only 2 ‘true’ E1 
ubiquitin activating enzymes, as the rest can activate other ULMs 44.   
Structurally, E1s are composed of an Adenylation domain containing 2 ThiF 
homology motifs (which bind ATP and Ubiquitin), the Catalytic Cysteine Domain 
(CCD) and the Ubiquitin Fold Domain (UFD, also known as the β-grasp fold) 51-53 
The UFD is particularly important as it is responsible for recognition and binding the 
relevant cognate E2-Conjugating Enzyme 52 49.  To date the regulation of these key 
components of the ubiquitination pathway, particularly in the context of how such E1 
proteins have the ability to be charged by their cognate ULM, have been intensely 
studied and structurally very revealing 44.  
 
E2 Conjugating Enzymes 
Next, the activated ubiquitin is transferred from the catalytic-cysteine of the 
E1 to the active-site cysteine of the E2 ubiquitin-conjugating enzyme.  E2s are at the 
centre of the ubiquitination cascade of which there are over 30 in number and 
characterised by the presence of a highly conserved catalytic UBC (Ubiquitin-
Congugating enzyme) domain of 150-200 amino-acids 54.  In a recent study 
addressing the activation of ubiquitin by specific E1- and E2-enzymes, 29 E2s 
accepted ubiquitin from UBE1 and UBA6 of which 14 were charged by UBE1 (but 
not by UBA6), 9 were charged by both UBE1 and UBA6 and 1 by UBA6 (but not 
UBE1), thus highlighting that each E1 has a distinct preference for a specific E2 49.  
Within the E2, it is the UBC domain that is of particular importance as it is 
responsible for specific binding to the relevant E3-ligase 55 
Structurally, UBC domains consists of α-helices, β-sheets and variable loop 
regions that surround an active-site catalytic domain 55.  Amino (N-Ex, N-) and 
Carboxyl (C-Ex, C-) terminal extensions have also been discovered to flank the 
catalytic domain (Figure 2) and shown to be important in steps such as substrate 
selection, subcellular localisation and dimerisation.  For example, with UBE2C, the 
N-terminal extension regulates the number of substrate lysines that become modifed 
by the E3 complex, whereas the N-terminal extension of E2-UbcH10 may also be 
important for ULM substrate selection and modulating UbcH10 catalytic activity 56,57.  
Alternatively, the C-terminal extensions may be generally involved in mediating 
protein-protein interactions with other members of the ubiquitination pathway.  For 
example, this region in E2-Ubc2 is important in mediating E3-selectivity for the Ubr1 
E3-ligase 58.  Also, in the case of (cdc34/UBE2R2) the acidic C-terminal extension, 
can be targeted for phosphorylation by CK2, which modulates SCF mediated Sic1 
ubiquitination and possibly localisation of this E2 59,60.  Concurrently, E2s can be 
divided into 4 classes according to the presence of these extensions 61,62. 
 
E3 Ubiquitin Ligases 
The final step during the ubiquitination of proteins is mediated by a number of 
E3-ligases, which result in the transfer of mono- or poly-ubiquitin to target proteins 
giving rise to the addition of K48-linked ubiquitin chains (where at least 4 are 
responsible for the 26S proteasomal degradation of proteins) 63, K63-linked chains-
which have been implicated in the regulation of a number of effects including protein 
trafficking, endocytosis and signal transduction 64,65. 
E3-ligases can be categorised into 3 distinct groups, the RING- (Really 
Interesting New Gene), the U box- and the HECT- (Homologous to E6-AP COOH 
Terminus) family of proteins, based on the presence of these conserved domains-
which not only contain the active-sites for these proteins but also serve as domains 
that can interact with ubiquitin-charged E2 enzymes 66. 
Within the SCF system, the RING (and U-box) E3s exists as an active 
polypeptide in a multi-component complex, for example the Skp1-Cullin-F-box 
protein complex-SCF 67.  Based upon their substrate-specificity and the discovery of 
genetic alterations, E3 ligases have been described to possess tumour suppressive 
(BRCA1 and Fbw7) and oncogenic properties (Mdm2, Skp2) and indeed do therefore 
play a key role in tumorigenesis 68.  Mechanistically, the RING finger E3s (to some 
extent) behave as substrate specific protein adaptors, due to them lacking a catalytic 
activity and consequently aid the transfer of active-ubiquitin from the E2 to the 
acceptor protein by positioning the substrate lysine residue in proximity to the E2-
ubiquitin conjugate.  Ubiquitin transfer occurs in a cyclical manner permitting 
liberating the E2 to be recharged with ubiquitin in a mechanism distinct to the HECT 
E3s 69. 
To date, 30 HECT E3-ligases have been identified and can be further sub-
classified into the NEDD4 E3-ligase family, based on the presence of WW-domains 
70.  Structurally, the HECT-E3s are composed of an amino-terminal C2-domain 
(responsible for calcium, lipid and protein interaction domain- 71, the WW-(which 
confers substrate specificity and mediates E3-substrate interactions) and the carboxyl 
HECT-domain (which interacts with the charged E2 72, thereby physically accepting 
charged ubiquitin prior to transferring it to the substrate (Figure 3).  More recently, it 
has been demonstrated that sequences other than the PxxY motif may also be 
responsible for binding the E3 HECT domain, as in the case of the Smad7 and Smurf2 
72.  
Structural information regarding E3 HECT ligase domains is limited and, to 
date, is available for E6AP73, WWP1 74, Smurf272 and Nedd4-L1 (PDB; Protein Data 
Bank).  In all cases, the HECT domain was seen to be bi-lobal and segregated into 
two distinct sub-domains comprising an amino- terminal lobe (N-lobe) of about 250 
amino acids that contains the E2 binding site and an approximately 100 amino acid C-
lobe containing the critical active site cysteine residue. A short linker between the N- 
and C-lobes provides rotational flexibility, an essential architectural facet that is 
required for stepwise transfer of ubiquitin from the charged E2 to the E3 and then 
onto the target substrate. More recently, the structure of the Nedd4 HECT:Ubiquitin 
complex suggests that non-covalent association with the growing ubiquitin chain at 
key residues within the HECT domain is flexible enough to promote both ubiquitin 
transfer and polyubiquitin processivity75,76. Undoubtedly, it is likely that further such 
detailed mechanistic insight into the key catalytic and tripartite ubiquitin transfer step 
within E3 ligases will prove to be the ‘holy-grail’ in addressing the future challenge to 
rationally design and develop any new E3/substrate specific inhibitors. 
 
Regulation of TGF-β  signals by ubiquitination 
Recently, significant research has focused on defining key regulatory 
intermediates in TGF signalling and the identification of their specific E3-ubiquitin 
ligases.  More specifically, the Smad7/TGFβ-R1 axis of regulation has been studied 
the most intensely due to this being a key negative regulatory step responsible for 
shutting down TGF signals.  Consequently, findings here have been extrapolated to 
define the modulation of the rSmads, which has culminated in revealing novel 
mechanisms that are spatially and temporally dependant. 
 
Regulatory SMADs2 and 3 
Initial studies clearly defined substrate localisation as being a key factor in 
mediating TGF signalling.  For example, rSmad activation is shown to be regulated 
by adaptor and anchoring proteins such as SMAD Anchor for Receptor Activation 
(SARA) 77 and Disabled-2 (Dab2) 78 and tubulin 79.  SARA was cloned as a binding 
partner to Smad2 and unveiled to modulate sub-cellular rSmad and its interaction and 
activation by TGFβRI.  Alternatively, Dab2 can interact with Smad2, TGFβ-RI and -
RII and was observed to restore the correct activity of Smad signalling in a TGF-
signalling-defective cell line. The tubulin:Smad interaction connects TGFβ signalling 
to the microtubule (MT) network, and it was shown that disruption of the MT network 
significantly enhances Smad2 phosphorylation.  As to whether these regulatory 
intermediates can modulate the ubiquitination of rSmads or the TGF-receptors 
remains to be demonstrated. 
Initial regulation of TGF signalling by E3s was derived from a study published 
in 1999, whereby the E3-ligase Smurf1 was cloned and identified to destabilise 
Smads-1 and -5 in a proteasomal-dependant manner 80.  Thereafter, by using a 
combination of database 81 and yeast 2 hybrid-screening 82, Smurf2 was cloned and 
shown to interact with Smads-1, -2, -3 and -4 and demonstrated to ubiquitinate Smad2 
causing it’s proteasomal breakdown. 
Subsequently, Smad2 has been shown to be ubiquitinated by the E3 NEDD4-2 
and which (more importantly) was demonstrated to ubiquitinate and degrade Smad7 
and TGFβ-R1 83.  Moreover, Smad2 can be degraded in a ubiquitination-dependant 
manner by Tui1/WWP1, an effect that can be potentiated by the expression of TGIF 
84.  Conversely, ITCH (or AIP4) has been demonstrated to be required for maximum 
TGF-β signalling by mediating the phosphorylation of Smad2 (in addition to 
regulating Smad2/TGFβ-R1 binding 85), highlighting that E3s do not always 
negatively modulate TGF-β signalling and that auxiliary proteins can be involved. 
Additionally, a new tier of Smad2/3 regulation by E3s has recently been elucidated 
involving their association with Nedd4L following TGFβ-induced Smad linker 
phosphorylation at a conserved WW domain binding phospho-Thr-Pro-Tyr motif 86. 
Moreover, this study demonstrated an extra level of hierarchical control involving by 
the kinase SGK1, which was shown to phosphorylate Nedd4L to block it’s binding to 
Smads2/3. This highlights a new aspect of E3-ligase regulation of Smads that fine-
tunes the potency and timescale of TGF-β activity, and also implicates a broader role 
for other kinases linked to unrelated signalling pathways in the direct control of E3 
ligases associated with TGF-β biological function. 
As well as receptor-regulated rSmads, Smad4 as a central component of the 
Smad signalling pathway, has been seen to be targeted by ubiquitination by the SCF-
βTRCP E3-complex 87,88 and by the E3, Jab1 89.  Here Smad4 was shown to undergo 
degradation, resulting in diminished cell cycle arrest in response to TGF-β 87.  Thus 
highlighting that the modulation of TGF signalling may be regulated simultaneously 
in an orchestrated manner by the NEDD and RING E3s.  
More recently, a new E3 regulator of TGF-β signalling known as WWP2 was 
demonstrated to modulate TGF-β signalling upon interacting with rSmads, resulting 
in their ubiquitination and degradation 14.  Here, an N- terminal isoform of WWP2 
(WWP2-N) was also reported and found to interact with the rSmads, and interestingly 
this complex was rapidly disrupted in a the presence of TGF-
β. Following over-expression of WWP2-N prior to TGFβ treatment, this culminated 
in reduced TGF-β/Smad-dependent transcriptional activity. Mechanistically, this was 
proposed to be by 2 proposed mechanisms; 1) by binding and activating full-length 
WWP2 in the absence of TGF-β to restrict rSmad levels; and/or 2) by directly binding 
rSmads and directing activated full-length WWP2 to them for ubiquitination in the 
presence of TGF-β (Figure 4a). Since Smad2/3 steady-state levels were rapidly 
depleted upon overexpression of WWP2-FL together with WWP2-N, it was 
postulated that the former might be the overriding mechanistic explanation for the 
action of WWP2-N on rSmad stability/activity. Although, an alternative possibility 
worth exploring in the future is that WWP2-N binding to rSmad in the presence of 
TGF-β could hinder association with other key signalling intermediates such as 
Smad4 or prevent rSmad binding to DNA. Interestingly, WWP2-N overexpression 
was not able to prevent EMT following a prolonged 4-day exposure to TGF-β. Thus 
the prime functional role for WWP2-N in this context might be to act to prevent or 
perhaps moderate the onset of TGF-β induced EMT. In this regard, expression 
profiling of WWP2-N by RT-PCR during TGF-β dependent EMT revealed that it 
disappeared at day-4 as this particular differentiation programme comes to an end. 
Thus highlighting that WWP2-isoforms, and WWP2-N in particular, may serve to co-
ordinate and orchestrate key biological outputs such as EMT, and that this activity 
might ultimately be globally determined by external input from other related and/or 
un-related signalling pathways that determine temporal patterns of E3-ligase isoform 
gene expression.  
Collectively, the above observations highlight the importance of Smad-
specific E3s, in addition to unveiling the mechanisms underlying how these E3s may 
be regulated by accessory proteins such as E3-ligase isoforms, and what biological 
relevance these intermediates may possess.  Whether such protein isoforms (or 
transcription spliced variants) exist for other E3s (or even E1 and E2s) is certainly an 
interesting area of research that may hold many answers to how the ‘ubiquitinome’ 
may be mechanistically regulated at the molecular level. 
 
Inhibitor SMAD 7 and TGFβ-R1 
Within the TGF-β signalling system, all of the Smad proteins (with the 
exception of Smad4) contain the PxxY motif, which can be recognised by the WW-
domains of the relevant substrate-specific Nedd E3-ligase 90.  Consequently, 
numerous E3s from the Nedd family have been unveiled to be important modulators 
of these key TGF signalling intermediates, the most characterised being the Smurf 
and WWP E3s.   
While originally cloned as a protein that can block the signalling of TGF-β 
receptors, Smad7 8,9 was later revealed to regulate ubiquitin-mediated TGFβ-R1 
degradation 91,92.  Subsequently, a number of studies have added to these findings by 
identification of Smurf1 as a key E3 involved in this-a protein from the Nedd4 family 
of E3s.  For example, Ebisawa et al. identified Smurf1 as a protein that interacts with 
TGFβ-R1 via Smad7, destabilising both of these proteins, thus highlighting a novel 
mechanistic role for Smad7 as an adaptor protein in down-regulation of Smurf1-
mediated TGF-β signalling 92.  Similarly, Smad7 can also act as a scaffolding protein 
for WWP1- and Nedd4-mediated ubiquitination of Smad4 93. 
Following the identification of another member of this E3 family, Smurf2 was 
observed to be less active in destabilising Smad7 but still potently destabilised TGFβ-
R1 adding further support to the role played by Smad7 as a scaffolding protein 91. 
Mechanistically, recent findings whereby a C-terminal Nuclear Export Signal (NES) 
present in Smad7 has been reported, highlights how Smad7 may utilise Crm1 to 
achieve efficient export of Smurf1 to TGFβ-R1 94.  Indeed, in the case of Smad7 and 
Smurf1, while proteins may act cooperatively by the modulation of the nuclear export 
of this complex being mediated by Smad7, the C2-domain of Smurf is believed to 
direct this complex to the plasma membraine, where the degradation of TGFβ-R1 can 
be mediated 95.  Similarly, WWP1 96 has been shown to stimulate the nuclear export 
of Smad7 followed by enhanced TGFβ-R1 binding and degradation, resulting in 
reduced TGF-mediated Smad2 phosphorylation and activation 97.  Consequently, this 
highlights an important role for the C2-domain of these Nedd4 E3s.  More recently, 
the Smurf1 C2 domain was shown to play a role in substrate selection as well as sub-
cellular localization 98, and the calcium binding properties of this domain could 
provide an important regulatory role within the Nedd4 family 99, representing an 
interesting avenue worth pursuing in the future. 
More recently, we have reported that the C2 domain may also stimulate the 
intermolecular activity of the full length E3, as in the case of WWP2-N and full length 
WWP2-FL 14.  Moreover, in this study the WWP2-C isoform, which lacks the C2-
domain was observed to be potently active in ubiquitination of Smad7, thereby 
highlighting an additional intramolecular inhibitory role for the C2-domain in 
modulation of WWP2-FL 14 and this adds a new layer of complexity of WWP2 
isoform and Smad regulation relevant to EMT and cancer (Figure 4b).  These 
observations are also in strong agreement with the regulatory mechanism proposed for 
Smurf2, where an intramolecular interaction between the C2- and the HECT- domain 
results in the inhibition of Smurf2 activity 100, thereby tightly regulating the activity of 
this E3-ligase and thus preventing the auto-activation and the uncontrollable loss of 
substrate. 
Collectively, these observations indeed highlight an important and complex 
regulatory role for the C2- and HECT-domains of the above E3s, in addition to 
emphasising the importance of E3-derived isoform proteins and their expression.  
Moreover, in the case of WWP2-N, expression studies were shown to modulate 
WWP2-mediated ubiquitination activity and Smad/TGF-β dependent gene expression, 
thus highlighting a novel paradigm in regulation of WWP2-FL and isoform-specific 
biological output 14. 
Another member of the Nedd family of HECT E3s recently demonstrated to 
enhance Smad7-TGFβ-R1 binding in the absence of ubiquitination activity, which 
results in down-regulation of TGF signals, is AIP4 (ITCH), highlighting that E3s may 
also take on the role as scaffolding proteins 101.  Moreover, a mechanism involving the 
autoubiquitination and degradation has also been suggested for ITCH 102, which may 
also be triggered upon JNK-mediated phosphorylation of this E3-ligase 103.  Similar 
autoubiquitination of E3s, as a ubiquitination-derived mechanism for self-regulation 
has also been proposed for WWP1 104 and WWP2 14. 
With the above in mind, other E3s from the RING-family of proteins have 
been demonstrated to modulate TGF-β signals.  In this context, Arkadia was found to 
negatively regulate Smad7 105,106; by the ubiquitination pathway (in the absence of 
TGFβ-R1 binding) causing the amplification of TGF-β signals, highlighting a 
mechanism distinct to the Smurf proteins 105 during EMT and renal fibrosis 107.  
Moreover, substrate specificity for Arkadia may also be modulated by Axin behaving 
as an accessory protein that aids the nuclear export of Smad7 108.  However, it is 
worth noting that Arkadia also acts independently of Smad7 in TGF-β pathway 
regulation to further regulate signal intensity by inducing ubiquitinantion and turnover 
of other substrates, including transcriptional co-repressors SnoN and c-Ski 109,110. 
Collectively, these findings highlight insight into how the Nedd and RING E3-
ligases may be regulated mechanistically by auxiliary and E3-derived isoform 
proteins.  In the case of WWP2-FL, the WWP2-N and WWP2-C proteins and their 
function in E3-mediated ubiquitination and destabilisation of SMAD-2, -3 and -7 
highlights that these isoforms do indeed play a very apparent role in TGF signalling 
which themselves may also be viewed as auxiliary proteins that work in cooperation 
with their full-length counterpart, WWP2-FL.  Moreover, identification and 
characterisation of such isoforms for other E3s (or even E1 and E2s) and their role in 
substrate-directed ubiquitination in addition to how these proteins may be regulated 
by the charged dynamics of E1 and E2 probably warrants further investigation.  
  
Regulation of the E1-E3 Ubiquitination pathway intermediates  
Whereas hundreds of E3-ligases have been identified and described, outside of 
the structural requirements for substrate recognition, events that physically modulate 
the biochemical activity of E3s are poorly understood and could therefore open up a 
novel regulatory niche that predisposes this pathway to therapeutic intervention in 
disease.  While we have touched upon, protein trafficking as being one possible 
mechanism of E3-protein regulation and the role of Smads behaving as scaffolding 
proteins, other modes of regulation of the ubiquitin pathway do indeed exist, such as 
by caspase cleavage 111. 
In this section we would like to focus on introducing the potential involvement 
of key ubiquitination protein isoforms and the regulatory roles they have been (or may 
have been) recognised to exhibit during ubiquitination. An interesting and important 
feature of HECT E3s is their ability to catalyze both substrate poly-/mono-
ubiquitination as well as auto-ubiquitination. In some cases, and dependent on the 
type of ubiquitin-chain linkage, this can culminate in protein turnover as well other 
non-proteasomal biological functions. This has particular relevance to not just 
highlighting targeted substrate recognition, but auto-ubiquitination of E3s as a key 
regulatory step in addition to the interplay and dynamics between E1-E3 proteins, 
which in this context is relatively poorly understood. 
To establish whether protein isoforms may potentially exist for the E1-E3 
enzymes as potential modulators of the ubiquitinome, we scrutinised the ENSEMBL 
database for the presence of alternative transcriptional (validated or non-validated) 
and protein-isoform variants for specific E1-E3 enzymes (Tables 1-3).  
In conjunction with recent findings reported by Jin et al 49 we firstly searched 
for variants for UBE1, UBA6 (E1 activating enzymes), secondly for their cognate E2-
conjugating enzymes which accept activated ubiquitin and thirdly, we specifically 
searched for spliced-variants for members of the Nedd4 E3 family.  Surprisingly, our 
findings highlighted that indeed protein isoforms do exist for this pathway and in 
most cases for which, very little has been reported. 
 
E1 Activating Isoforms 
In the case of the two E1s, UBE1 and UBA6, scrutinising the ENSEMBL 
database revealed transcription spliced variants that may encode protein isoforms 
which may have carboxyl-terminal deletions-with respect to the full-length UBE1 
protein (Table 1).  As these derivatives may posses defective UFDs, it is likely that 
the interaction of these predicted E1s with their cognate E2s may be impaired.  The 
existence of these isoforms is supported by findings which reported that total E1-
ubiquitin activating enzyme UBE1 can exist as two isoforms, E1a (117kd) and E1b 
(110 kDa)-arising from possible alternative start sites within the mRNA 47,112.  Both of 
these isoforms were observed to be exclusively compartmentalised in the nucleus 
(Ela) or the cytoplasm (E1b) 113, primarily reflecting the essential requirement for E1a 
activity during distinct compartmentalised phases of the cell cycle.  Also, E1a was 
modified post-translationally by phosphorylation 114, in a cell cycle-dependant manner 
115).  How these isoforms modulate the mechanistic activation of ubiquitin and the 
subsequent transfer of charged ubiquitin to the E2 conjugating enzyme remains to be 
demonstrated. 
In the instance of UBA6, no validated protein isoforms derived from this gene 
locus have been described in the literature.  However, 2 alternative transcripts were 
detected within the ENSEMBL database (Table 1), predicted to encode the first 389 
aa, which putatively encode the inter-domain dimerisation motif (as part of the 
conserved Ube1 repeat)-but lack the CCD and UFD domains  (UBA6-002).  Whereas, 
UBA6-005 may encode a protein theoretically lacking a significant amount of the N- 
and C-region of UBA6, while still retaining the ATP binding motifs and the active-
site cysteine residue.  As differences in the N-terminal ThiF region may alter 
adenylation for the ULM by the E1 and taking into consideration that some E1s 
require the N-terminal region for dimerisation, the prediction would be that UBA6-
005 may certainly exhibit some unique biochemical properties with respect to whether 
it is functionally active or may behave in a dominant-inhibitory manner. 
 
E2 Conjugating Enzyme Isoforms 
For the E2 Ubiquitin conjugating enzymes, the ENSEMBL database revealed 
in the instance of UBE2-A, -C, -D2, -D3, -E1, -G2, -H, -J2, -Q2 and -W2 that 
validated protein-isoforms of these intermediates do indeed exist (Table 2), which 
predictably may have altered specificity for the E1 activating enzyme UBE1. 
Additionally, predicted and non-validated transcription spliced-variants of UBE2 -E2, 
-E2B, -E3, -D4 and -L3 were also identified for which protein isoforms are yet to be 
confirmed. 
Similarly, for E2s that are specific for the E1 UBA6, validated protein-
isoforms were detected for UBE2-E2A, -G2, -2C, -D2, -D3, -E1 and non-validated 
transcription-isoforms for UBE-2B, -D4, -E2, -E3, -L3, -2Z (Use1), (see Table 2).   
Here, of interest is the E2 isoform (which lacks the N-or C-terminal regions) 
that is shared by UBE1 and UBA6, such as UBE2D (-see Jin et al 49), for which 4 
validated protein-isoform variant exists.  One of these, called UBE2D2-002 contains 
subtle amino-acid substitutions and lacks the N-terminal 30aa.  Bearing in mind the 
possible function of the N-terminal extensions present in the E2s, could the UBE1 and 
UBA6 proteins have different specificities for this E2 protein-isoform, in addition to 
this isoform possessing impaired biochemical properties? 
Moreover, UBE2B-005 and -008 transcripts encode potential proteins of 
respective sizes 138 and 141 aa, that lack the N- and C- terminal residues.  May these 
potential isoform proteins consequently have impaired affinity for UBE1 and UBA6 
E1-activating enzymes (or even E3-ligases)?  
 
E3 Ligase Isoforms 
For the E3s, there is accumulating literature recognising the presence of 
protein isoforms within the Nedd family, including Nedd4L 116, Nedd4-2 117, WWP1 
118 and WWP2 14.  While expressed as paralogues 116, and unlike Nedd4, Nedd4L 
contains an N-terminal deletion, which results in it having a partial C2-domain and is 
catalytically more active than Nedd4.  Not only could this be due to the N-terminal 
having defective intramolecular inhibitory properties it could also be due to the 
incomplete C2-domain being unable to target its substrate protein to the plasma 
membrane (as in the case of Smad7/Smurf1).  However, other regulatory mechanisms 
such as whether it can form homodimers and whether it’s ability to be modulated 
correctly by the E2 conjugating enzyme remains to be seen.  No such validated 
protein-isoforms or splice-variants have been detected for Smurf2, whereas several 
additional non-validated transcription splice-variants have been identified for WWP1, 
ITCH, NEDL1, NEDL2 and await to be confirmed for their protein products (Table 
3). 
As demonstrated by Soond et al, WWP2 proteins isoforms WWP2-N and –C 
are expressed in addition to full-length WWP2 14.  While their mechanistic interplay 
in ubiquitination of Smads -2, -3, -7 and WWP2 autoubiquitination have been 
highlighted, very little is known regarding their biochemical regulation by the E2s.  
For example do they modulate any regulatory mechanism for the E2s?  Is the 
specificity of WWP2-C altered for any particular E2 and ULM-charged E2 in relation 
to WWP2-FL?  Do these WWP2-isoforms have differing subcellular localisation that 
may imply protein trafficking as being fundamental in their regulation?  Do these 
isoforms modulate the stability of TGFβ-R1 in a Smad7-dependent manner, as in the 
case of Smad7-Smurf?  Is phosphorylation important for WWP2 isoform regulation, 
auto-ubiquitination and/or substrate recognition of WWP2? Are other accessory 
proteins such as Nedd4 family-interacting proteins (NDFIPs119) differentially 
controlled by distinct E3 isoforms? These are all very interesting and valid questions 
for which the answers are eagerly awaited. At the same time, it is also worth 
considering the diverse substrate specificities of E3-ligases, perhaps linked to 
isoform-specific inter-regulation, and particularly in the context of disease-specific 
function. For example, the WWP2 E3-ligase has a growing list of known 
physiological substrates including Oct4 120,121, DMT1 122, RNA Polymerase II 123, 
Goosecoid 124, and most recently PTEN 125. Thus, it is also timely to begin to address 
the question of E3-isoform substrate preference in vivo, and in appropriate 
physiological settings. 
In contrast to the HECT E3s, the RING E3s and their isoforms are extensive in 
number and in some cases have been well documented.  For example, βTRCP is 
encoded by 2 genes (βTRCP1 and 2), which give rise to 2 protein variants, -beta and –
gamma, which are present in the cytoplasm and nucleus, respectively 126, highlighting 
subcellular specific activities.  Fbw7 127, SIAH 128, RUNX1 129 , BRCA 130, RBCK 131 
and Pir2B 132 are also other RING E3-ligases that protein-isoform have been reported 
for.  As to how these variants may be modulated by the E2s remain largely 
uncharacterised. 
In TGF-β signalling, while some of the regulatory E3-isoforms identified to 
date may not have been validated (Table 3), some protein-isoforms certainly have and 
warrant further investigation into the precise mechanistic role played by them within 
the ubiquitination pathway using model systems.  Taken with what little is known 
about how the alternative variants of these proteins are generated, the transcriptional 
regulation of such variants certainly does also warrant further study and may 
consequently hold great mechanistic potential.  This is based upon the unique 
properties the protein variants may exhibit in the different stages of tumour 
progression, such as EMT and cancer cell invasiveness.  
 
 
Conclusions and Future Directions 
In the rapidly growing field of ubiquitination research, where great strides are 
being made in extrapolating the findings of basic research into translational biology, it 
certainly seems that the future holds great hope.  With this in mind, and while initial 
observations point to a simple sequence of events that lead to protein ubiquitination, 
the reporting and characterisation of E1-E3 isoform variants is set to change the way 
we view the underlying regulation of the ubiquitination pathway and their respective 
substrates.  Based on our initial findings, reported herein and in the case of E3-
isoforms (like WWP2-N or WWP2-C), protein-isoforms of this pathway may have a 
unique biological and regulatory role to play during onset of disease and 
development.  Consequently, is it too premature to ask ‘whether the E3 (or even the 
E1 and E2) isoforms may modulate the ‘ubiquitinome?’.  While research into this 
phenomenon is in its infancy, the answer to this is question at this juncture in time is 
‘quite possibly’.  Indeed the literature does suggest that structurally, the UBE1 
isoforms 112 may have differing biochemical properties based upon their sub-cellular 
location and phosphorylation status.  In the case of E2-isoforms, these may modulate 
E3 enzymatic activity directly or as competitive inhibitors towards activated E1 and 
E3 isoforms. 
With this in mind and taken with how fast this field of research is developing, 
it is therefore justified that the nomenclature in this rapidly exciting field should also 
be permitted to evolve from contextualising all that embodies ubiquitination via the 
colloquial ‘ubiquitinome’ to possibly the ‘isoubiquitinome’-all that embodies 
ubiquitination in light of the existence of protein-isoforms.  Consequently, this should 
paint a more accurate (and tangible) picture of how the ubiquitination pathway is 
regulated and thus highlight more specific and potential targets to aid therapeutic 
development within this exciting field of research. 
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Figure 1: The TGF signalling pathway highlighting TGFβ-RII receptor occupation by 
TGF-β, the trans-phosphorylation of TGFβ-R1 and Smad4-mediated gene regulatory 
events dictated by Smads2 and 3.  Smad7 is highlighted as a central negative-
regulator of signalling. 
 
Figure 2:  The ubiquitination pathway highlighting the identity of the E1-E3 enzymes 





Figure 3:  The structural architecture of the Nedd4 family of E3-ligases. 
  
Figure 4a:  Proposed modulation of Smad-ubiquitination by the WWP2 E3-ligase 
isoforms in regulating TGF-β-dependent EMT.  WWP2-N has been proposed to be an 
intermolecular activator of WWP2-FL (in the absence of TGF-β stimulation), which 
reduces EMT by destabilising the rSMADs.  However, in the presence of TGF-β 
stimulation, this regulatory step can be downregulated, giving rise to less active 
WWP2 and enhanced rSMAD-mediated EMT. 
 
 
Figure 4b: WWP2-C was observed to have enhanced Smad7 destabilisation 
properties in comparison to WWP2-FL, highlighting an intramolecular inhibitory role 
for the C2 domain. Consequently, expression of WWP2-C results in enhanced EMT 
of cells in comparison to the WWP2-FL protein. 
 
E1-Name Transcript ID Length-bp Protein ID Length-aa CCDS 
UBA1-002 ENST00000377351 3466 ENSP00000366568 1058 CCDS14275 
UBA1-003 ENST00000377269 2497 ENSP00000366481 506 - 
UBA1-004 ENST00000412206 1148 ENSP00000415033 271 - 
UBA1-005 ENST00000427561 671 ENSP00000397816 173 - 
UBA1-006 ENST00000457753 809 ENSP00000404796 195 - 
UBA1-007 ENST00000442035 1054 ENSP00000389583 284 - 
UBA1-008 ENST00000451702 1706 ENSP00000401101 234 - 
      
UBA6-001 ENST00000322244 6455 ENSP00000313454 1052 CCDS3516 
UBA6-002 ENST00000420827 1664 ENSP00000399234 389 - 
UBA6-005 ENST00000505673 816 ENSP00000421984 272 - 
 
Table 1:  Identification of transcriptional splice variants of E1-ubiquitin activating 
enzymes.  ENSEMBL and Consensus CDS (CCDS) accession numbers are 
highlighted in blue. 
 
E2-Name Transcript ID Length-bp Protein ID Length-aa CCDS 
UBE2A-001 ENST00000371558 1796 ENSP00000360613 152 CCDS14580 
UBE2A-002 ENST00000346330 612 ENSP00000335027 122 CCDS14581 
UBE2A-003 ENST00000371569 2643 ENSP00000360624 77 CCDS14582 
      
UBE2B-001 ENST00000265339 2515 ENSP00000265339 152 CCDS4174 
UBE2B-005 ENST00000506787 500 ENSP00000426364 138 - 
UBE2B-008 ENST00000507277 644 ENSP00000425137 141 - 
      
UBE2C-001 ENST00000356455 850 ENSP00000348838 179 CCDS13370 
UBE2C-003 ENST00000335046 737 ENSP00000335674 161 CCDS13371 
UBE2C-004 ENST00000372568 914 ENSP00000361649 140 CCDS13374 
UBE2C-005 ENST00000243893 476 ENSP00000243893 50 CCDS13373 
UBE2C-006 ENST00000352551 665 ENSP00000333975 150 CCDS13372 
      
UBE2D2-001 ENST00000398733 2702 ENSP00000381717 147 CCDS43369 
UBE2D2-002 ENST00000505548 1113 ENSP00000424941 118 CCDS47275 
UBE2D3-001 ENST00000453744 3990 ENSP00000396901 147 CCDS3660 
UBE2D3-002 ENST00000343106 2389 ENSP00000345285 148 CCDS3661 
      
UBE2E1-001 ENST00000306627 1511 ENSP00000303709 193 CCDS2638 
UBE2E1-002 ENST00000346855 1398 ENSP00000329113 176 CCDS2639 
      
UBE2G2-001 ENST00000345496 3106 ENSP00000338348 165 CCDS13714 
UBE2G2-005 ENST00000330942 721 ENSP00000331384 137 CCDS33586 
      
UBE2H-001 ENST00000355621 5151 ENSP00000347836 183 CCDS5814 
UBE2H-006 ENST00000473814 535 ENSP00000419097 152 CCDS47710 
      
UBE2J2-001 ENST00000349431 1733 ENSP00000305826 259 CCDS14 
UBE2J2-015 ENST00000400930 1021 ENSP00000383719 275 CCDS15 
UBE2J2-016 ENST00000400929 1057 ENSP00000383718 207 CCDS16 
      
UBE2Q2-001 ENST00000267938 3130 ENSP00000267938 375 CCDS10286 
UBE2Q2-202 ENST00000426727 2971 ENSP00000400960 359 CCDS45309 
      
UBE2W-001 ENST00000517608 8426 ENSP00000428813 151 CCDS47874 
UBE2W-002 ENST00000419880 2281 ENSP00000397453 162 CCDS47875 
 
Table 2: Identification of the E2-conjugating enzyme transcription splice-variants and 
protein isoforms.  ENSEMBL and Consensus CDS (CCDS) accession numbers are 
highlighted in blue.  
 
E3-Name Transcript ID Length-bp Protein ID Length-aa CCDS 
SMURF1-001 ENST00000361125 5737 ENSP00000354621 757 CCDS34690 
SMURF1-002 ENST00000361368 5581 ENSP00000355326 731 CCDS34689 
SMURF2-201 ENST00000262435 3866 ENSP00000262435 748 CCDS32707 
      
NEDD4-001 ENST00000338963 7019 ENSP00000345530 1247 CCDS10156 
NEDD4-006 ENST00000435532 5760 ENSP00000410613 900 CCDS45265 
      
NEDD4L-204 ENST00000357895 8378 ENSP00000350569 967 CCDS45874 
NEDD4L-205 ENST00000382850 8413 ENSP00000372301 955 CCDS45873 
NEDD4L-206 ENST00000400345 8473 ENSP00000383199 975 CCDS45872 
NEDD4L-207 ENST00000431212 8300 ENSP00000389406 854 CCDS45875 
NEDD4L-208 ENST00000435432 8406 ENSP00000393395 834 CCDS45876 
      
WWP1-201 ENST00000265428 3362 ENSP00000265428 922 CCDS6242 
WWP1-202 ENST00000341922 2972 ENSP00000340564 792 - 
WWP1-203 ENST00000349423 2708 ENSP00000342665 704 - 
WWP1-204 ENST00000436619 2163 ENSP00000415672 180 - 
      
ITCH-001 ENST00000374864 6401 ENSP00000363998 862 CCDS13234 
ITCH-002 ENST00000262650 3730 ENSP00000262650 903 - 
      
HECW1-001 ENST00000395891 6839 ENSP00000379228 1606 CCDS5469 
HECW1-002 ENST00000453890 5169 ENSP00000407774 1572 - 
HECW1-007 ENST00000429529 415 ENSP00000413336 139 - 
HECW1-201 ENST00000265522 6781 ENSP00000265522 346 - 
      
HECW2-001 ENST00000260983 6926 ENSP00000260983 1572 CCDS33354 
HECW2-002 ENST00000409111 6690 ENSP00000386775 1216 - 
HECW2-003 ENST00000452031 620 ENSP00000409918 133 - 
HECW2-004 ENST00000427457 568 ENSP00000395770 118 - 
 
Table 3: Identification of the NEDD E3-ligase transcription splice-variants and 
protein isoforms. ENSEMBL and Consensus CDS (CCDS) accession numbers are 
highlighted in blue. 
